Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.44 |
| ▸ | CDK2AP1 | O14519 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564531 | 0.97 | CHEK1 (0.42) | CHEK1CDK2AP1 | |
| SCHEMBL1563966 | 0.86 | CHEK1 (0.42) | CHEK1CDK2AP1 | |
| SCHEMBL1406007 | 0.85 | CHEK1 (0.38) | CHEK1 | |
| SCHEMBL1562835 | 0.85 | CHEK1 (0.63) | CHEK1CDK2AP1 | |
| SCHEMBL1563538 | 0.83 | CHEK1 (0.62) | CHEK1CDK2AP1 | |
| SCHEMBL5004723 | 0.82 | CHEK1 (0.53) | CHEK1CDK2AP1 | |
| SCHEMBL4994950 | 0.82 | CHEK1 (0.53) | CHEK1CDK2AP1 | |
| SCHEMBL4991815 | 0.80 | CHEK1 (0.55) | CHEK1CDK2AP1 | |
| SCHEMBL1563036 | 0.80 | USP30 (0.40) | CHEK1 | |
| SCHEMBL4994981 | 0.79 | CHEK1 (0.52) | CHEK1CDK2AP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305671-A1 | Thiophene and thiazole derivatives as CHK1 inhibitors | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20060281666-A1 | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | CHEK1, CHKA, CHEK2 | CHEK1 1/4885CDK2AP1 222/4885 |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | TPMT, ABCG2, TYMP | CHEK1 297/4885CDK2AP1 2722/4885 |
| US-20060281666-A1 | Substitute thiophenes and uses therof | TYMP, TPMT, MGMT | CHEK1 602/4885CDK2AP1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.